FiercePharma1d
Fierce Pharma Asia—Merck's collabs with Daiichi, Eisai deliver readouts; Granules hit with FDA manufacturing observations
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Merck Keytruda with Eisai’s Lenvima succeeds in late-stage trial for liver cancer
Merck’s (NYSE:MRK) anti-PD-1 therapy Keytruda as part of a combination regimen with Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) ...
Cure Today6d
Lenvima Regimen Offers Benefits in Intermediate Stage Liver Cancer
Patients with intermediate-stage liver cancer may benefit from receiving a Lenvima-Keytruda combination with transarterial ...
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...
The Pharma Letter4d
ESMO 2024: Eisai and Merck report positive Phase III results
Eisai and Merck & Co have reported positive data from the LEAP-012 trial for their combination of Lenvima (lenvatinib) and ...
ENDPOINTS NEWS5d
Keytru­da and Lenvi­ma still have an­oth­er hill to climb fol­low­ing lat­est da­ta drop
Merck's bumpy six-year relationship with Eisai's anti-cancer medication Lenvima landed on somewhat better footing in Spain ...
MedPage Today on MSN5d
Another Possible Treatment Option for Intermediate-Stage Liver Cancer
Median PFS increased from 10 months with TACE to 14.6 months with the addition of lenvatinib (Lenvima) and pembrolizumab ...
Medscape6d
A New Option to Treat Intermediate Hepatocellular Carcinoma?
Intermediate-stage hepatocellular carcinoma remains a challenge to treat. The new findings may lead to a new treatment ...